ID: MRFR/HC/5746-CR | January 2019 | Region: Global | 156 pages
MRFR’s study projects a strong growth for the global pericarditis market during the forecast period (2018-2023). Growing prevalence of cardiac disorders worldwide and improving healthcare infrastructure in emerging economies creating opportunities for market players. Americas continues to be the key investment destination for drug companies, with countries such as the U.S., Canada, Mexico and Brazil occupying the leading spots. On a global level, the pericarditis market stood at a valuation of USD 1,750.38 Mn in 2017. Opportunities are likely to get better in emerging markets such as China and India in the forthcoming years. Rising healthcare spending and increased healthcare penetration is providing an impetus to the market in these countries.
This MRFR study presents a holistic viewpoint of the global pericarditis market. A revenue forecast for five-years (2018-2023) is also included in the study. It thoroughly discusses all the elements that may have some sort of impact on the market during the assessment period. The scope of the discussion also covers different types of pericarditis such as acute pericarditis, chronic pericarditis and recurrent pericarditis. In addition, study shed a light on diagnosis and treatment options available.
Novartis International AG, Pfizer Inc., AstraZeneca Plc., PerkinElmer, Inc., Sanofi, Johnson & Johnson Services, Inc., Reckitt Benckiser Group Plc, FUJIFILM Holdings Corporation, Bayer AG, Merck & Co., Inc. and Allergan plc.
The report offers insights into the leading market players and presents an assessment of their current market position. Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives is also available in the report.
MRFR relies on a robust research model for conducting industry analysis. The analysis pattern may differ from sector to sector, but the fundamental structure remains unshaken. Emphasis is placed on maintaining a deep-diving research dogma. For this, interviews and meetings are conducted with opinion holders, thought leaders, and key executives. Also, data is collected from secondary research materials such as SEC filings, dossiers, paid database services, annual report published by industry leaders, etc. The gathered data undergoes a multi-level evaluation process making it error-free. In addition, both top-down and bottom-up approaches are applied to add value to research findings.
For the scope of the research, MRFR’s report offers a comprehensive segmental analysis of the global market for pericarditis
By Diagnosis and Treatment
By End User
Frequently Asked Questions (FAQ) :
Pericaditis market is projected to grow at a 7.96% CAGR between 2018-2023.
Pericaditis market is predicted to touch USD 2,741.39 million by 2023.
The Americas is expected to lead the pericaditis market.
Favorable reimbursement and the advent of robot-assisted cardiac surgeries are the key factors driving the pericaditis market.
Certain side effects may limit the pericaditis market.
The Global pericarditis market has a significant growth potential. As per the research findings, the market is projected to stand at over USD 2, 700 Mn by the year 2023 up from USD 1,750.38 Mn in 2017. Factors such as increasing prevalence of cardiovascular diseases and improving reimbursement policies are deeply linked with the uptick in demand for pericarditis treatment and care. There is a sharp rise in the incidence of cardiovascular diseases, a backlash of rising obesity and diabetes cases. The risk of developing a pericarditis issue is significantly high if the individual is suffering from any of the chronic ailments mentioned above. As per the American Heart Association, nearly 92.1 million Americans were diagnosed with cardiovascular diseases in 2017. It also stated that the prevalence is found to be higher in men than in women. Furthermore, in the same year, more than 92% of the patients exhibited major symptoms of heart diseases such as chest pain, heartburns, and strokes.
Improved penetration of healthcare services in third-world countries is also reflecting favorably on the market. Moreover, policy markers in developing countries are actively focusing on bolstering the healthcare domain as a part of delivering better governance. In recent years, medical reimbursement policies have continued to improve in both advance and developing countries. As per the Center for Disease Control and Prevention (CDC),65% of the people under the age of 65 had private insurance while 26.35% of people had public insurance in the US in 2017. Despite the increased market opportunity, players are likely face challenges in front such as drug safety and product approvals.
Segmental analysis of the market is conducted on the basis of type, diagnosis & treatment, end-user and region. Based on type, the pericarditis market is segmented into acute pericarditis, chronic pericarditis, and recurrent pericarditis. The acute pericarditis segment is projected to reach a market valuation of USD 1,365.94 Mn by 2023-end. Acute pericarditis refers to the inflammation of the pericardial sac and is a common pericardium disorder. The recurrent pericarditis segment is expected to exhibit the highest CAGR during the assessment period.
Based on diagnosis and treatment, the pericarditis market is segmented into diagnosis and treatment. The diagnosis segment is further sub-segment into electrocardiogram (ECG), echocardiogram, computerized tomography (CT) and X-Ray. The treatment segment is further sub-segmented into medication and surgical treatment. The treatment is likely to retain its dominant position throughout the forecast period as well as reflect a strong growth rate.
Based on end user, the global pericarditis market is segmented into hospitals and clinics, medical institutes & research organizations, and others. The hospitals and clinics segment is projected to reach USD 1,323.16 million by the end of 2023, increasing at a CAGR of 8.05%from 2018 to 2023. In 2017, the hospital segment accounted 48.01% market share in terms of value. The medical institutes & research organization segment currently holds the second spot and is projected to witness a relatively higher CAGR.
On the basis of region, the global pericarditis market has been segmented into four key regions, which include Americas, Europe, Asia-Pacific (APAC), and the Middle East and Africa (MEA). The Americas currently account for the largest share of the global pericarditis market. On the back of rising healthcare spending and growing insurance coverage, demand for pericarditis treatment has continued to grow. Moreover, presence of robust healthcare system and a massive patient pool is creating opportunities for market players. North America is followed by Europe - the second largest market for pericarditis. Fueled buy the increased prevalence of pericarditis in both West and East European countries, the region’s market reached a valuation of USD 540.97 Mn in 2017. Meanwhile, the market in APAC is expected to post the highest CAGR during the assessment period. Rising level of awareness coupled with improving healthcare services has opened new avenues for market players operating in the region.
Some of the key companies operating in the global pericarditis market include Pfizer Inc., Reckitt Benckiser Group Plc, Novartis International AG, Allergan plc., AstraZeneca Plc., Bayer AG, PerkinElmer, Inc., FUJIFILM Holdings Corporation, Merck & Co., Inc., Sanofi, and Johnson & Johnson Services, Inc.
Global Pericarditis Market: Company Landscape
The global pericarditis market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all the players competing to gain the market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, quality, and reliability. It is decisive for vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive and growing market environment.
The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, vendors should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional and foreign players with small market shares also have a presence. The international players are likely to strengthen their presence worldwide through acquisitions during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new products and to increase the global market share.
Many leading players are concentrated in the Americas owing to the strengthening healthcare system, well-established market, high healthcare expenditures, and numerous opportunities for growth. These players have expanded their market in other regions as well. Furthermore, companies such as Pfizer Inc., AstraZeneca Plc, Novartis International AG, Allergan plc., and Merck & Co., Inc. are top five market players in this market. Apart from this, Bayer AG, Reckitt Benckiser Group Plc., PerkinElmer, Inc., FUJIFILM Holdings Corporation, Sanofi, and Johnson & Johnson Services, Inc. are some of the well-established players in the global pericarditis market.
Pfizer Inc. (Pfizer) is a leading research-based biopharmaceutical company that develops medicines and vaccines for a wide range of medical disciplines including cardiology, immunology, oncology, diabetology/endocrinology, and neurology. Pfizer additionally teams up with healthcare providers, governments, and local communities to support and expand access to reliable and affordable healthcare around the world. The company operates worldwide in the Americas, Europe, Asia-Pacific, and the Middle East and Africa. In July 2017 Pfizer Inc. extended the collaboration with Catalent, Inc, a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products for the development and manufacture of Advil Liqui-Gels.
Novartis International AG (Novartis) is a Swiss multinational pharmaceutical company that researches, develops, manufactures, and distributes a wide range of healthcare products globally. The company operates through three segments, namely, innovative medicines, Sandoz, and Alcon. The company provides products that find applications in cancer, cardio-metabolic, immunology and dermatology, ophthalmology, neuroscience, and respiratory diseases.
Allergan plc. (Allergan) is a pharmaceutical company with a motive of manufacturing, developing, and commercializing pharmaceutical products, biological products, and devices for patients worldwide. The company has a wide range of products which provide effective treatments for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories. The company has operations across the globe in regions such as Europe, Africa, Americas, and Asia-Pacific.
Merck & Co., Inc. (Merck) is also known as MSD outside the US and Canada. The company operates through its four segments, namely, pharmaceutical, animal health, healthcare services, and alliances. The company offers therapeutic and preventive agents to treat arthritis and pain, cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, and other diseases. Merck works with clients and works in more than 140 countries to provide inventive healthcare products.